On Instagram, Avery fought back her tears while explaining her situation.
The singer warned her followers ‘to be careful’
Avery, an American singer-songwriter, uploaded two videos on her social media sites warning followers ‘to be careful’ with Ozempic unless prescribed.
Avery’s real name is Anna Iannitelli
In her first social media post, Avery stated that she had gone for a checkup since she had ‘been off Ozempic for two months now’ and wanted to see if her body was in ‘better condition’.
She was shocked when she discovered a bone-thinning illness
She recently posted an Instagram video in which she claimed to have been diagnosed with osteoporosis after supposedly taking Ozempic for a year.
She claims she was left ‘in shock’ when she was told she had osteoporosis, which, according to the Mayo Clinic, can cause bones to ‘become weak and brittle — so fragile that a fall or even slight stresses such as leaning over or coughing might cause a break’.
Ozempic is actually not a licensed weight reduction drug
According to UC Davis Health, the medical center of the University of California, Ozempic is not licensed for weight reduction, but a medicine known as Wegovy is, which has a higher dose of semaglutide and is covered by both Ozempic and Wegovy.
The after-effect was much bigger than she had expected
Avery said: “I guess Ozempic can cause bone density loss, and I didn’t think that that would happen to me, because I was only on it for a year, but I have significant bone loss.
“I have osteoporosis and osteopenias that I don’t know. There’s, like, several of them that I have, and I just wasn’t… I just wasn’t, like, expecting… I wasn’t expecting that.”
She then warns her fans not to make her mistake
In her post, the 30-year-old said: “I made a mistake. I take responsibility for my actions. Please learn from mine.”
“Please please please be careful with Ozempic if you are not someone that needs to take it,” she added.
RELATED STORIES
The pharmaceutical company defends itself against any misuse
Novo Nordisk, Ozempic’s manufacturing company, told UNILAD: “Novo Nordisk does not condone, suggest, or encourage misuse of any of our medicines outside of their approved indications. Ozempic (semaglutide injection) is not licensed for the treatment of weight loss.
“We understand the health challenges this individual has faced and the safety and wellbeing of patients taking our medicines is our top priority.
“We strongly recommend that all patients stay in close contact with their healthcare professional for proper diagnosis, ongoing guidance, and careful monitoring.”
